• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Breastfeeding Mothers Taking Antiepileptic Drugs – Is it Safe for Infants?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • There is no clear consensus on the safety of antiepileptic drugs (AEDs) during breastfeeding due to limited data of medication levels in breast milk
  • Birnbaum et al. (JAMA Neuro., 2019) sought to determine the extent of AED exposure via breastfeeding

METHODS:

  • Prospective cohort study (2012 to 2016)
    • Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs [MONEAD] observational multicenter study
  • Participants
    • Mothers: Epilepsy diagnosis | 14 to 45 years | <20 weeks | IQ scores >70 points
    • Infants: Enrolled at birth
  • Exposures
    • AED exposure in infants who were breastfed
  • Study design
    • Women followed up through pregnancy and 9 months postpartum
    • Children followed up until 6 years of age
    • AED concentrations from infants and mothers at the same visit, 5 to 20 weeks after birth
    • AEDS: Carbamazepine | Carbamazepine-10,11-epoxide | Levetiracetam | Lamotrigine | Oxcarbazepine | Topiramate | Valproate | zonisamide
    • infant values < plasma-equivalent lower limits of quantification (LLoQ) were represented as half of LLoQ
    • Breastfeeding measurements: Total duration of overall daily breastfeeding sessions | Volume of pumped breast milk (bottle)
  • Primary outcome
    • The percentage of infant-to-mother concentration of AED

RESULTS:

  • 164 matching infant-mother concentration pairs
  • 49% of all antiepileptic drug concentrations in nursing infants were less than the lower limit of quantification
  • Median percentage of infant-to-mother concentration
    • Ranged from 0.3% (carbamazepine epoxide) to 44.2% (Zonisamide)
  • Maternal concentration association with infant concentration  
    • Lamotrigine concentration was associated with infant concentration (P < 0.001)
    • Levetiracetam concentration was not associated with infant concentration
    • Analysis only done for these 2 AEDs, because there were not enough infant samples that were >LLoQ for the other AEDs  

CONCLUSION:

  • Overall, AED concentrations in blood samples of breastfed infants were much lower than that of their mothers
  • For carbamazepine, oxcarbazepine, valproic acid, levetiracetam, and topiramate, infant levels were less than respective LLoQs
  • The authors of this study conclude that their findings support the continued breastfeeding of infants by mothers receiving AEDs
    • The benefits of breastfeeding are very well established
    • Previous studies have not shown adverse effects when the mother was receiving AEDs

Learn More – Primary Sources:

Antiepileptic Drug Exposure in Infants of Breastfeeding Mothers With Epilepsy

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Try it Free  »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Antiepileptic Drugs: What is the Impact on Risk for Birth Defects
Adverse Perinatal Outcomes and Epilepsy: Is it the Disorder or the Treatment?
Antiepileptic Medications and Risk for Congenital Malformations

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site